{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:32Z","timestamp":1790790212261,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-2_CSP-08"],"award-info":[{"award-number":["Z-2_CSP-08"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-024-02513-3","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:59:25Z","timestamp":1724309965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Liver stiffness as a prognostic parameter and tool for risk stratification in advanced cardiac transthyretin amyloidosis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-7122","authenticated-orcid":false,"given":"Sandra Michaela","family":"Ihne-Schubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Johannes","family":"Steinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"2513_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","volume":"16","author":"S Ihne","year":"2019","unstructured":"Ihne S, Morbach C, Obici L, Palladini G, Stork S (2019) Amyloidosis in heart failure. Curr Heart Fail Rep 16:285\u2013303","journal-title":"Curr Heart Fail Rep"},{"key":"2513_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68:1014\u20131020","journal-title":"J Am Coll Cardiol"},{"key":"2513_CR3","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806","journal-title":"Eur Heart J"},{"key":"2513_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cjca.2019.12.020","volume":"36","author":"F Cappelli","year":"2020","unstructured":"Cappelli F, Martone R, Gabriele M et al (2020) Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems. Can J Cardiol 36:424\u2013431","journal-title":"Can J Cardiol"},{"key":"2513_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00392-017-1167-1","volume":"107","author":"FAD Siepen","year":"2018","unstructured":"Siepen FAD, Bauer R, Voss A et al (2018) Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol 107:158\u2013169","journal-title":"Clin Res Cardiol"},{"key":"2513_CR6","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","volume":"30","author":"G Merlini","year":"2016","unstructured":"Merlini G, Lousada I, Ando Y et al (2016) Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia 30:1979\u20131986","journal-title":"Leukemia"},{"key":"2513_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/0886022X.2013.875815","volume":"36","author":"Z Yilmaz","year":"2014","unstructured":"Yilmaz Z, Yildirim Y, Oto F, Aydin FY, Aydin E, Kadiroglu AK, Yilmaz ME (2014) Evaluation of volume overload by bioelectrical impedance analysis, NT-proBNP and inferior vena cava diameter in patients with stage 3&4 and 5 chronic kidney disease. Ren Fail 36:495\u2013501","journal-title":"Ren Fail"},{"key":"2513_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.20452\/pamw.2969","volume":"125","author":"K Schwermer","year":"2015","unstructured":"Schwermer K, Hoppe K, Radziszewska D et al (2015) N-terminal pro-B-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn 125:560\u2013569","journal-title":"Pol Arch Med Wewn"},{"key":"2513_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021460","volume":"99","author":"WY Park","year":"2020","unstructured":"Park WY, Park S, Kim YW, Jin K (2020) Clinical efficacy of biomarkers for evaluation of volume status in dialysis patients. Medicine (Baltimore) 99:e21460","journal-title":"Medicine (Baltimore)"},{"key":"2513_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"2513_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ahj.2020.12.009","volume":"233","author":"J Vaishnav","year":"2021","unstructured":"Vaishnav J, Hubbard A, Chasler JE et al (2021) Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J 233:122\u2013131","journal-title":"Am Heart J"},{"key":"2513_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D et al (2021) Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail 23:895\u2013905","journal-title":"Eur J Heart Fail"},{"key":"2513_CR13","first-page":"159","volume":"117","author":"S Ihne","year":"2020","unstructured":"Ihne S, Morbach C, Sommer C, Geier A, Knop S, Stork S (2020) Amyloidosis-the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int 117:159\u2013166","journal-title":"Dtsch Arztebl Int"},{"key":"2513_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","volume":"30","author":"R Rettl","year":"2023","unstructured":"Rettl R, Duca F, Binder C et al (2023) Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy. Amyloid 30:127\u2013137","journal-title":"Amyloid"},{"key":"2513_CR15","first-page":"21","volume":"108","author":"AM Rocha","year":"2017","unstructured":"Rocha AM, Ferreira SG, Nacif MS, Ribeiro ML, Freitas MR, Mesquita CT (2017) Speckle tracking and transthyretin amyloid cardiomyopathy. Arq Bras Cardiol 108:21\u201330","journal-title":"Arq Bras Cardiol"},{"key":"2513_CR16","unstructured":"Bundes\u00e4rztekammer (B\u00c4K) KBK, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz \u2013 Langfassung, 3. Auflage. Version 3"},{"key":"2513_CR17","unstructured":"Brozena SC, Jessup M (2003) The new staging system for heart failure. What every primary care physician should know. Geriatrics 58: 31\u201336; quiz 8"},{"key":"2513_CR18","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1002\/ehf2.14038","volume":"9","author":"JK Dhillon","year":"2022","unstructured":"Dhillon JK, Fong MW, Fong TL (2022) Use of liver stiffness measurements in acute decompensated heart failure: new applications of a non-invasive technique. ESC Heart Fail 9:2800\u20132807","journal-title":"ESC Heart Fail"},{"key":"2513_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.amjcard.2013.10.018","volume":"113","author":"T Taniguchi","year":"2014","unstructured":"Taniguchi T, Sakata Y, Ohtani T et al (2014) Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure. Am J Cardiol 113:552\u2013558","journal-title":"Am J Cardiol"},{"key":"2513_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1253\/circj.CJ-14-0929","volume":"79","author":"H Nishi","year":"2015","unstructured":"Nishi H, Toda K, Miyagawa S et al (2015) Novel method of evaluating liver stiffness using transient elastography to evaluate perioperative status in severe heart failure. Circ J 79:391\u2013397","journal-title":"Circ J"},{"key":"2513_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/ejcts\/ezw419","volume":"51","author":"N Kashiyama","year":"2017","unstructured":"Kashiyama N, Toda K, Nakamura T et al (2017) Evaluation of right ventricular function using liver stiffness in patients with left ventricular assist device. Eur J Cardiothorac Surg 51:715\u2013721","journal-title":"Eur J Cardiothorac Surg"},{"key":"2513_CR22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.healun.2015.05.022","volume":"34","author":"A Potthoff","year":"2015","unstructured":"Potthoff A, Schettler A, Attia D et al (2015) Liver stiffness measurements and short-term survival after left ventricular assist device implantation: a pilot study. J Heart Lung Transplant 34:1586\u20131594","journal-title":"J Heart Lung Transplant"},{"key":"2513_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1253\/circj.CJ-15-1200","volume":"80","author":"T Yoshitani","year":"2016","unstructured":"Yoshitani T, Asakawa N, Sakakibara M et al (2016) Value of virtual touch quantification elastography for assessing liver congestion in patients with heart failure. Circ J 80:1187\u20131195","journal-title":"Circ J"},{"key":"2513_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1253\/circj.CJ-17-1344","volume":"82","author":"Y Saito","year":"2018","unstructured":"Saito Y, Kato M, Nagashima K et al (2018) Prognostic relevance of liver stiffness assessed by transient elastography in patients with acute decompensated heart failure. Circ J 82:1822\u20131829","journal-title":"Circ J"},{"key":"2513_CR25","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00380-018-1318-y","volume":"34","author":"K Omote","year":"2019","unstructured":"Omote K, Nagai T, Asakawa N et al (2019) Impact of admission liver stiffness on long-term clinical outcomes in patients with acute decompensated heart failure. Heart Vessels 34:984\u2013991","journal-title":"Heart Vessels"},{"key":"2513_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cardfail.2019.01.020","volume":"25","author":"A Soloveva","year":"2019","unstructured":"Soloveva A, Kobalava Z, Fudim M, Ambrosy AP, Villevalde S, Bayarsaikhan M, Garmash I, Naumenko M (2019) Relationship of liver stiffness with congestion in patients presenting with acute decompensated heart failure. J Card Fail 25:176\u2013187","journal-title":"J Card Fail"},{"key":"2513_CR27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jcmg.2017.10.022","volume":"12","author":"T Taniguchi","year":"2019","unstructured":"Taniguchi T, Ohtani T, Kioka H et al (2019) Liver stiffness reflecting right-sided filling pressure can predict adverse outcomes in patients with heart failure. JACC Cardiovasc Imaging 12:955\u2013964","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"2513_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051440","volume":"13","author":"SM Ihne-Schubert","year":"2024","unstructured":"Ihne-Schubert SM, Goetze O, Gerstend\u00f6rfer F et al (2024) Cardio-hepatic interaction in cardiac amyloidosis. J Clin Med 13(5):1440","journal-title":"J Clin Med"},{"key":"2513_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s44162-024-00028-z","volume":"3","author":"SM Ihne-Schubert","year":"2024","unstructured":"Ihne-Schubert SM, Morbach C, Papagianni A et al (2024) AmyKoS\u2014a German real-world prospective cohort study of patients with suspected and proven amyloidosis. J Rare Dis 3:4","journal-title":"J Rare Dis"},{"issue":"75","key":"2513_CR30","first-page":"659","volume":"2021","author":"European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis -","year":"2021","unstructured":"European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - (2021) update. J Hepatol 2021(75):659\u2013689","journal-title":"J Hepatol"},{"key":"2513_CR31","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s10620-016-4079-4","volume":"61","author":"DH Kaswala","year":"2016","unstructured":"Kaswala DH, Lai M, Afdhal NH (2016) Fibrosis assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci 61:1356\u20131364","journal-title":"Dig Dis Sci"},{"key":"2513_CR32","first-page":"12","volume":"7","author":"R Stauber","year":"2009","unstructured":"Stauber R (2009) Nichtinvasive Diagnose der Leberfibrose bei chronischen Hepatopathien. J f\u00fcr Gastroenerologische und Hepatologische Erkrankungen 7:12\u201317","journal-title":"J f\u00fcr Gastroenerologische und Hepatologische Erkrankungen"},{"key":"2513_CR33","first-page":"S41","volume":"12","author":"AM Ozercan","year":"2022","unstructured":"Ozercan AM, Ozkan H (2022) Vibration-controlled transient elastography in NAFLD: review study. Euroasian J Hepatogastroenterol 12:S41\u2013S45","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"2513_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jhep.2009.11.018","volume":"52","author":"G Millonig","year":"2010","unstructured":"Millonig G, Friedrich S, Adolf S et al (2010) Liver stiffness is directly influenced by central venous pressure. J Hepatol 52:206\u2013210","journal-title":"J Hepatol"},{"key":"2513_CR35","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/hep.22577","volume":"48","author":"G Millonig","year":"2008","unstructured":"Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Buchler MW, Seitz HK, Mueller S (2008) Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48:1718\u20131723","journal-title":"Hepatology"},{"key":"2513_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058742","volume":"8","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, Garcia-Pagan JC, Bosch J (2013) Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 8:e58742","journal-title":"PLoS One"},{"key":"2513_CR37","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ejrad.2013.02.011","volume":"82","author":"A Potthoff","year":"2013","unstructured":"Potthoff A, Attia D, Pischke S et al (2013) Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). Eur J Radiol 82:1207\u20131212","journal-title":"Eur J Radiol"},{"key":"2513_CR38","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/j.1478-3231.2010.02355.x","volume":"30","author":"J Boursier","year":"2010","unstructured":"Boursier J, Cales P (2010) Clinical interpretation of Fibroscan(R) results: a real challenge. Liver Int 30:1400\u20131402","journal-title":"Liver Int"},{"key":"2513_CR39","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11739-022-02958-2","volume":"17","author":"F Perfetto","year":"2022","unstructured":"Perfetto F, Zampieri M, Fumagalli C, Allinovi M, Cappelli F (2022) Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Intern Emerg Med 17:957\u2013969","journal-title":"Intern Emerg Med"},{"key":"2513_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","volume":"2","author":"RK Cheng","year":"2020","unstructured":"Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los SJ, Leedy D, Maurer MS (2020) Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol 2:414\u2013424","journal-title":"JACC CardioOncol"},{"key":"2513_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2023-002310","volume":"10","author":"M Aurich","year":"2023","unstructured":"Aurich M, Bucur J, Vey JA et al (2023) Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy. Open Heart 10:e002310","journal-title":"Open Heart"},{"key":"2513_CR42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jcmg.2016.04.008","volume":"10","author":"S Barros-Gomes","year":"2017","unstructured":"Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, Pellikka PA, Villarraga HR (2017) Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imag 10:398\u2013407","journal-title":"JACC Cardiovasc Imag"},{"key":"2513_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","volume":"13","author":"M Boldrini","year":"2020","unstructured":"Boldrini M, Cappelli F, Chacko L et al (2020) Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imag 13:909\u2013920","journal-title":"JACC Cardiovasc Imag"},{"key":"2513_CR44","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","volume":"60","author":"SJ Buss","year":"2012","unstructured":"Buss SJ, Emami M, Mereles D et al (2012) Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 60:1067\u20131076","journal-title":"J Am Coll Cardiol"},{"key":"2513_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","volume":"43","author":"OC Cohen","year":"2022","unstructured":"Cohen OC, Ismael A, Pawarova B et al (2022) Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. Eur Heart J 43:333\u2013341","journal-title":"Eur Heart J"},{"key":"2513_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jaccao.2020.05.014","volume":"2","author":"RH Falk","year":"2020","unstructured":"Falk RH, Singh V, Dorbala S (2020) Evaluating prognosis in AL amyloidosis: can LV strain play a role? JACC CardioOncol 2:232\u2013235","journal-title":"JACC CardioOncol"},{"key":"2513_CR47","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10554-015-0711-1","volume":"31","author":"K Hu","year":"2015","unstructured":"Hu K, Liu D, Nordbeck P et al (2015) Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis. Int J Cardiovasc Imag 31:1401\u20131412","journal-title":"Int J Cardiovasc Imag"},{"key":"2513_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaccao.2020.05.012","volume":"2","author":"K Lee Chuy","year":"2020","unstructured":"Lee Chuy K, Drill E, Yang JC et al (2020) Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis. JACC CardioOncol 2:223\u2013231","journal-title":"JACC CardioOncol"},{"key":"2513_CR49","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/ehf2.13909","volume":"9","author":"F Oike","year":"2022","unstructured":"Oike F, Usuku H, Yamamoto E et al (2022) Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis. ESC Heart Fail 9:1976\u20131986","journal-title":"ESC Heart Fail"},{"key":"2513_CR50","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","volume":"129","author":"CC Quarta","year":"2014","unstructured":"Quarta CC, Solomon SD, Uraizee I et al (2014) Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129:1840\u20131849","journal-title":"Circulation"},{"key":"2513_CR51","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1253\/circj.CJ-20-1064","volume":"85","author":"G Robin","year":"2021","unstructured":"Robin G, Cognet T, Bouisset F et al (2021) Value of longitudinal strain to identify wild-type transthyretin amyloidosis in patients with aortic stenosis. Circ J 85:1494\u20131504","journal-title":"Circ J"},{"key":"2513_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A et al (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139:431\u2013443","journal-title":"Circulation"},{"key":"2513_CR53","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y et al (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146:1657\u20131670","journal-title":"Circulation"},{"key":"2513_CR54","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412","journal-title":"Circulation"},{"key":"2513_CR55","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1002\/ehf2.14164","volume":"9","author":"H Yang","year":"2022","unstructured":"Yang H, Li R, Ma F et al (2022) An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction. ESC Heart Fail 9:4280\u20134290","journal-title":"ESC Heart Fail"},{"key":"2513_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.amjcard.2023.01.014","volume":"192","author":"J Longinow","year":"2023","unstructured":"Longinow J, Buggey J, Jacob M, Martens P, Hanna M, Tang WHW, Bhattacharya S (2023) Significance of pulmonary hypertension in cardiac amyloidosis. Am J Cardiol 192:147\u2013154","journal-title":"Am J Cardiol"},{"key":"2513_CR57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010078","volume":"16","author":"P Martens","year":"2023","unstructured":"Martens P, Bhattacharya S, Longinow J, Ives L, Jacob M, Valent J, Hanna M, Tang WHW (2023) Hemodynamic profiling and prognosis in cardiac amyloidosis. Circ Heart Fail 16:e010078","journal-title":"Circ Heart Fail"},{"key":"2513_CR58","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ijcard.2012.09.128","volume":"168","author":"JP Lassus","year":"2013","unstructured":"Lassus JP, Siirila-Waris K, Nieminen MS et al (2013) Long-term survival after hospitalization for acute heart failure\u2013differences in prognosis of acutely decompensated chronic and new-onset acute heart failure. Int J Cardiol 168:458\u2013462","journal-title":"Int J Cardiol"},{"key":"2513_CR59","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.amjcard.2019.05.031","volume":"124","author":"A Younis","year":"2019","unstructured":"Younis A, Mulla W, Goldkorn R, Klempfner R, Peled Y, Arad M, Freimark D, Goldenberg I (2019) Differences in mortality of new-onset (De-Novo) acute heart failure versus acute decompensated chronic heart failure. Am J Cardiol 124:554\u2013559","journal-title":"Am J Cardiol"},{"key":"2513_CR60","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/00015385.2020.1747178","volume":"76","author":"R Pranata","year":"2021","unstructured":"Pranata R, Tondas AE, Yonas E, Vania R, Yamin M, Chandra A, Siswanto BB (2021) Differences in clinical characteristics and outcome of de novo heart failure compared to acutely decompensated chronic heart failure - systematic review and meta-analysis. Acta Cardiol 76:410\u2013420","journal-title":"Acta Cardiol"},{"key":"2513_CR61","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","volume":"18","author":"F Salinaro","year":"2017","unstructured":"Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL (2017) Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imag 18:1057\u20131064","journal-title":"Eur Heart J Cardiovasc Imag"},{"key":"2513_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hep.27981","volume":"63","author":"EM Koehler","year":"2016","unstructured":"Koehler EM, Plompen EP, Schouten JN et al (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 63:138\u2013147","journal-title":"Hepatology"},{"key":"2513_CR63","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/gut.2010.221382","volume":"60","author":"D Roulot","year":"2011","unstructured":"Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, Beaugrand M (2011) Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 60:977\u2013984","journal-title":"Gut"},{"issue":"1138\u201345","key":"2513_CR64","volume":"16","author":"L Caballeria","year":"2018","unstructured":"Caballeria L, Pera G, Arteaga I et al (2018) High prevalence of liver fibrosis among european adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol 16(1138\u201345):e5","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2513_CR65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","volume":"61","author":"VW Wong","year":"2012","unstructured":"Wong VW, Chu WC, Wong GL et al (2012) Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61:409\u2013415","journal-title":"Gut"},{"key":"2513_CR66","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033094","volume":"13","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Nitsche C, Porcari A et al (2024) Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis. J Am Heart Assoc 13:e033094","journal-title":"J Am Heart Assoc"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02513-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T07:08:09Z","timestamp":1724310489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02513-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":66,"alternative-id":["2513"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02513-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sandra Ihne-Schubert: S. Ihne-Schubert received financial reimbursement for consulting, advisory board activities, speaker honoraries, and\/or travel support to attend scientific meetings by Akcea Therapeutics, Alnylam, Pfizer, Janssen-Cilag, and Takeda, and further research funding from Pfizer and Akcea Therapeutics. An internship was supported by ONLUS. She was fellow of the local Clinician Scientist program of the IZKF W\u00fcrzburg. Caroline Morbach: C. Morbach reports research cooperation with the University of W\u00fcrzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, Germany; she is supported by the German Research Foundation (DFG) within the Comprehensive Research Center 1525 'Cardio-immune interfaces' (453989101, project C5) and receives financial support from the Interdisciplinary Center for Clinical Research\u2014IZKF W\u00fcrzburg (advanced clinician-scientist program; AdvCSP 3). She further received advisory and speakers honoraria as well as travel grants from Tomtec, Alnylam, AKCEA, Pfizer, Boehringer Ingelheim, SOBI, AstraZeneca, NovoNordisk, Alexion, Janssen, and EBR Systems; principal investigator in trials sponsored by Alnylam, Bayer, NovoNordisk, and AstraZeneca. <i>Oliver Goetze:<\/i> No conflicts of interest. <i>Vladimir Cejka:<\/i> No conflicts of interest. <i>Maximilian Steinhardt:<\/i> No conflicts of interest. <i>Stefan Frantz:<\/i> S. Frantz received consultancy and lecture fees as well as travel expenses from AMGEN Europe, AstraZeneca, Bayer Vital, Boehringer Ingelheim, Bristol-Meyers Squibb GmbH, Daiichi Sankyo, MSD, Novartis, Pfizer, Sanofi, Servier, and Vifor. <i>Hermann Einsele:<\/i> No conflicts of interest. <i>Claudia Sommer:<\/i> C. Sommer received speaker honoraria from Alnylam. <i>Stefan St\u00f6rk:<\/i> S. St\u00f6rk received research support by the German Federal Ministry of Education and Research (BMBF). He has received consultancy and lecture fees from Akcea, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, NovoNordisk, Pfizer. His department received case payments for study participation from Akcea Therapeutics, Alnylam, and IONIS. <i>Torben Schubert:<\/i> No conflicts of interest. <i>Andreas Geier:<\/i> A. Geier served as a steering committee member or advisor for AbbVie, Alexion, Bayer, BMS, Eisai, Falk, Gilead, Heel, Intercept, Ipsen, Merz, MSD, Novartis, Pfizer, Roche, and Sanofi-Aventis and as speaker for AbbVie, Advanz, Alexion, BMS, Burgerstein, CSL Behring, Falk, Gilead, Intercept, Merz, MSD, Novartis, NovoNordisc, and Roche. He received research support from Intercept and Falk (both NAFLD CSG), Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}